Order Article Reprints

Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, Cony-Makhoul P, Coiteux V, Sutton L, Abarah W, et al. Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia. Pharmaceutics. 2022; 14(8):1676. https://doi.org/10.3390/pharmaceutics14081676

Johnson-Ansah, Hyacinthe, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, and et al. 2022. "Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia" Pharmaceutics 14, no. 8: 1676. https://doi.org/10.3390/pharmaceutics14081676

Johnson-Ansah, H., Maneglier, B., Huguet, F., Legros, L., Escoffre-Barbe, M., Gardembas, M., Cony-Makhoul, P., Coiteux, V., Sutton, L., Abarah, W., Pouaty, C., Pignon, J.-M., Choufi, B., Visanica, S., Deau, B., Morisset, L., Cayssials, E., Molimard, M., Bouchet, S., ... Rousselot, P., on behalf of the Groupe Français pour la LMC (Fi-LMC). (2022). Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia. Pharmaceutics, 14(8), 1676. https://doi.org/10.3390/pharmaceutics14081676